🌍·8h agoRegulatory
Tecovirimat SIGA (μονοϋδρική τεκοβιριμάτη): περιορισμός της ένδειξης λόγω έλλειψης αποτελεσματικότητας που καταδείχθηκε σε τυχαιοποιημένες κλινικές δοκιμές σε ασθενείς με mpox
Publisher
E
EOF Greece
Greece
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on eof.gr
Leave the platform to read the original full article on the publisher site.
Source: EOF Greece
Scope: Regulatory
Related coverage
More related coverage
MHRA UK·3h ago
Class 4 Medicines Defect Notification: Milpharm Limited, Loperamide hydrochloride 2 mg Orodispersible Tablets, EL(26)A/23
MHRA UK·4h ago
Pre market medical devices regulation – stakeholder impact survey
MHRA UK·5h ago
Consultation on the regulation of Gene therapy medicinal products
EOF Greece·6h ago